Medical cannabis or marijuana officially became legal statewide on July 1, with MSP quickly emerging as the de facto hub for sales and cultivation. Two MSP-area companies,
Minnesota Medical Solutions (MinnMed) and
LeafLine Labs, are leading the way.
According to the
Minnesota Department of Health, more than 200 healthcare practitioners were certified to recommend patients for medical marijuana during the first month of registrations. About 100 patients are certified to purchase medical marijuana statewide, though that number is expected to increase as the state works through its backlog of patient applications and more providers come online.
MinnMed’s flagship clinic, where medical marijuana cardholders can purchase cannabis oil and other derivatives, recently
moved into the old League of Catholic Women space in downtown Minneapolis. LeafLine’s first clinic is located in suburban Eagan.
Each organization plans three more dispensaries around the state: MinnMed in Moorhead, Rochester and Eden Prairie; LeafLine in St. Paul, St. Cloud and Hibbing. LeafLine grows its product at a tightly controlled, 24-acre facility in suburban Cottage Grove, while MinnMed works a state-of-the-art greenhouse complex in rural Otsego.
Combined, LeafLine and MinnMed have
already raised about $30 million in venture capital funding, with more potentially in the works. But with some of the nation’s most restrictive medical cannabis laws here in Minnesota, it could be a while before funders see a return on their investment. Unlike California, Colorado, Washington State and other pro-cannabis states, Minnesota — even liberal MSP — won’t have ostentatious storefront dispensaries or open-to-the-public cannabis clubs anytime soon.
‘‘The [national] industry doesn’t do it this way,’’ MinnMed principal Dr. Kyle Kingsley
said in a recent interview with the Boston Globe. ‘‘It’s all new.’’
The law also sets strict qualifying standards for prospective patients. Patients need to demonstrate — and healthcare providers must confirm — that their conditions are truly debilitating or life threatening. Qualifying conditions include glaucoma; Crohn’s disease; cancer or cancer treatment associated with nausea, vomiting, wasting and/or severe pain; HIV/AIDS; seizure disorders; severe muscle spasms, such as caused by multiple sclerosis; ALS; and Tourette’s Syndrome.
To promote safer modes of ingestion and prevent patients from smoking their medicine, Minnesota’s law forbids direct sales of plant material. Instead, producers are required to extract the plant’s active ingredients, condensing them into potent oils that can be incorporated into pill capsules, oral sprays, tinctures, suspensions and oils designed to be heated, vaporized and inhaled.
Dosages vary between and within each mode. Both MinnMed and LeafLife offer detailed dosing instructions to patients and healthcare providers, with MinnMed advocating a “start low, go slow” approach for patients unfamiliar with marijuana’s effects. Over time, each patient is encouraged to develop a customized dosing regimen in consultation with their healthcare provider.
“Different patients have different needs, and there are a lot of compounds in cannabis that are helpful to patients,” said Kingsley in
a recent interview with KSTP. “[W]e want to...make these medications for specific patients.”